Skip to main content

Table 1 Baseline characteristics of the fondaparinux and enoxaparin groups

From: Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Characteristics Fondaparinux (n = 430) Enoxaparin (n = 463) P
Age (year) 57.29 ± 9.39 58.16 ± 9.58 0.170
Male [n(%)] 328 (76.3) 363 (78.2) 0.486
Weight (kg) 72.04 ± 12.08 72.64 ± 13.05 0.487
Hypertension [n(%)] 245 (57.2) 276 (59.5) 0.448
Diabetes [n(%)] 98 (22.8) 94 (20.3) 0.357
Stroke [n(%)] 14 (3.3) 11 (2.4) 0.423
Prior myocardial infarction [n(%)] 50 (11.6) 74 (15.9) 0.060
Current smoker [n(%)] 224 (52.1) 246 (53.0) 0.782
ACS [n(%)]    
 Unstable angina 216 (50.2) 296 (68.3) 0.658
 Non-ST-elevation ACS 52 (12.1) 49 (10.6) 0.477
 ST-elevation MI 162(37.7) 119 (25.6) <0.001
Target vessel position [n(%)]    
 Left Main 53 (12.3) 66 (14.2) 0.397
 Left Anterior Descending 278 (64.7) 295 (63.6) 0.771
 Left Circumflex 36 (8.4) 39 (8.4) 0.978
 Right Coronary Artery 46 (10.9) 45 (9.7) 0.629
PCI    
 Average stent diameter (mm) 3.03 ± 0.40 3.06 ± 0.40 0.181
 Average length of stents (mm) 27.17 ± 5.96 27.58 ± 5.89 0.293
 Average number of stents 1.85 ± 0.96 1.89 ± 1.02 0.627
Transradial artery invasive [n(%)] 378 (87.9) 408 (87.9) 0.991
Tirofiban (d) 1.84 ± 0.66 1.90 ± 0.62 0.495
Fondaparinux/enoxaparin (d) 4.75 ± 1.81 4.57 ± 1.75 0.168
Laboratory examination    
 APTT (s) 33.39 ± 5.86 32.97 ± 5.57 0.271
 Prothrombin time (s) 12.97 ± 1.38 12.90 ± 1.07 0.381
 HDL-C (mmol/L) 1.19 ± 0.44 1.18 ± 0.58 0.639
 Creatinine (mmol/L) 87.50 ± 18.71 91.02 ± 15.02 0.116
 PLT (×109/L) 212.29 ± 56.09 212.50 ± 51.13 0.954
  1. ACS Acute coronary syndrome, MI Myocardial infarction, PCI Percutaneous coronary intervention, APTT Activated partial thromboplastin time, HDL-C High-density lipoprotein cholesterol. All values are expressed as means ± SD. P < 0.05 was considered to indicate statistical significance